<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01108185</url>
  </required_header>
  <id_info>
    <org_study_id>P12-060</org_study_id>
    <nct_id>NCT01108185</nct_id>
  </id_info>
  <brief_title>Evaluation of the Treatment With Klacid®SR in Patients With Lower Respiratory Tract Infection</brief_title>
  <official_title>Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis or Mild Community-acquired Bronchopneumonia in Common Clinical Practice in the Slovak Republic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this post-marketing observational study (PMOS) is to describe the relief of
      symptoms, tolerability and compliance of treatment with Klacid®SR in a dose 1000 mg once
      daily in patients with lower respiratory tract infection or in patients with acute
      exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This PMOS will be conducted in a prospective, open-label, single-country, multicenter format.
      The investigational sites will be consulting rooms of GPs (general practitioner),
      pneumologists and centers with experience in the treatment of patients with lower respiratory
      tract infection, AECB (acute exacerbation of chronic bronchitis) and CAP (mild
      community-acquired pneumonia). Since this will be a PMOS, Klacid®SR will be prescribed in
      usual manner in accordance with the terms of the local market authorization with regards to
      dose, population and indication as well as local guidelines. The decision to prescribe or not
      prescribe Klacid®SR would be taken prior to entry of a subject in the study.

      Follow-up of patients should enable two patient visits during this period.
      Screening/Inclusion Visit will be performed when the decision to start the treatment with
      Klacid®SR is made. Inclusion of patient in the study will succeed at day 0 (S/I Visit). The
      Second Visit will follow 10 - 16 days after the Screening/Inclusion Visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Compliance (Was the Dosage Followed - Yes, no)</measure>
    <time_frame>Day 10 - 16</time_frame>
    <description>Compliance was assessed by asking physicians if participants took their medication as directed and if not, the reason for noncompliance. The number of participants that completed their course of therapy or did not complete due to noncompliance is reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Tolerability of Klacid SR Will be Assessed by Evaluation of Adverse Events</measure>
    <time_frame>Day 0 through Days 10 - 16</time_frame>
    <description>The number of participants experiencing adverse events, serious adverse events, or adverse events leading to study discontinuation are summarized. See Reported Adverse Events for additional details.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Temperature</measure>
    <time_frame>Day 0</time_frame>
    <description>Body temperature was measured at Day 0 (Baseline) and 10 to 16 days later (Visit 2). Increased body temperature was defined as body temperature greater than or equal to 37 degrees Celsius/98.6 Fahrenheit. The percentage of participants with increased or normal body temperature at Day 0 (Baseline) is summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Temperature</measure>
    <time_frame>Day 10 - 16</time_frame>
    <description>Body temperature was measured at Day 0 (Baseline) and 10 to 16 days later (Visit 2). Increased body temperature was defined as body temperature greater than or equal to 37 degrees Celsius/98.6 Fahrenheit. The percentage of participants with increased or normal body temperature at Visit 2 is summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough and Its Character</measure>
    <time_frame>Day 0</time_frame>
    <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The presence of cough and the type of cough (productive or irritating) was determined by the treating physician based on clinical judgment. The number of participants with each type of cough or no cough at Baseline is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough and Its Character</measure>
    <time_frame>Day 10 - 16</time_frame>
    <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The presence of cough and the type of cough (productive or irritating) was determined by the treating physician based on clinical judgment. The number of participants with each type of cough or no cough at Visit 2 is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnoea</measure>
    <time_frame>Day 0</time_frame>
    <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The treating physicians used their clinical judgment to determine the presence of dyspnoea (difficulty breathing) and whether it occurred while resting or after exertion. The number of participants with each type of dyspnoea or with no dyspnoea at Baseline is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnoea</measure>
    <time_frame>Day 10 - 16</time_frame>
    <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The treating physicians used their clinical judgment to determine the presence of dyspnoea (difficulty breathing) and whether it occurred while resting or after exertion. The number of participants with each type of dyspnoea or with no dyspnoea at Visit 2 is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Auscultation</measure>
    <time_frame>Day 0</time_frame>
    <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The treating physician used their clinical judgment to determine the presence of abnormal breathing sounds such as wheezing or crackles using auscultation (listening for sounds within the body, usually with a stethoscope in the chest, neck or abdomen). The number of participants with each type of breath sound at Baseline is summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Auscultation</measure>
    <time_frame>Day 10 - 16</time_frame>
    <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The treating physician used their clinical judgment to determine the presence of abnormal breathing sounds such as wheezing or crackles using auscultation (listening for sounds within the body, usually with a stethoscope in the chest, neck or abdomen). The number of participants with each type of breath sound at Visit 2 is summarized.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3181</enrollment>
  <condition>Tracheitis</condition>
  <condition>Tracheobronchitis</condition>
  <condition>Bronchitis</condition>
  <condition>Chronic Bronchitis</condition>
  <condition>Community-acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Acute Respiratory Infections</arm_group_label>
    <description>Slovak patients with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients included in this PMOS will be those with acute tracheitis, acute
        tracheobronchitis, acute bronchitis, mild CAP and acute exacerbation of chronic bronchitis
        with infectious etiology caused probably by an atypical agent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men, women at least 18 years old

               -  with acute tracheitis,

               -  acute tracheobronchitis,

               -  acute bronchitis,

               -  mild community-acquired pneumonia or

               -  acute exacerbation of chronic bronchitis

        Exclusion Criteria:

          -  Patients with known hypersensitivity to macrolide antibiotics

          -  Patients with documented renal impairment (creatinine clearance under 30 ml/min).

          -  Patients with documented liver parenchyma impairment (AST, ALT and GMT &gt; 3x higher
             level in comparison with the norm)

          -  Concomitant therapy with the following drugs: astemizole, cisapride, colchicine,
             pimozide, terfenadine and ergotamine or dihydroergotamine

          -  Pregnancy

          -  Breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Hloska, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37753</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37758</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37806</name>
      <address>
        <city>Bardejov</city>
        <zip>08501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38052</name>
      <address>
        <city>Bojnice</city>
        <zip>97201</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37830</name>
      <address>
        <city>Bratislava</city>
        <zip>81107</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37828</name>
      <address>
        <city>Bratislava</city>
        <zip>81108</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37823</name>
      <address>
        <city>Bratislava</city>
        <zip>82007</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37824</name>
      <address>
        <city>Bratislava</city>
        <zip>82007</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37827</name>
      <address>
        <city>Bratislava</city>
        <zip>82007</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37826</name>
      <address>
        <city>Bratislava</city>
        <zip>82101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37680</name>
      <address>
        <city>Bratislava</city>
        <zip>82103</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37681</name>
      <address>
        <city>Bratislava</city>
        <zip>82106</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37825</name>
      <address>
        <city>Bratislava</city>
        <zip>82106</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37829</name>
      <address>
        <city>Bratislava</city>
        <zip>82107</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37732</name>
      <address>
        <city>Bratislava</city>
        <zip>83101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37831</name>
      <address>
        <city>Bratislava</city>
        <zip>83299</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37833</name>
      <address>
        <city>Bratislava</city>
        <zip>83299</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37729</name>
      <address>
        <city>Bratislava</city>
        <zip>83309</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37840</name>
      <address>
        <city>Bratislava</city>
        <zip>83309</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37679</name>
      <address>
        <city>Bratislava</city>
        <zip>84101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37835</name>
      <address>
        <city>Bratislava</city>
        <zip>84102</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37839</name>
      <address>
        <city>Bratislava</city>
        <zip>84102</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37834</name>
      <address>
        <city>Bratislava</city>
        <zip>84104</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37832</name>
      <address>
        <city>Bratislava</city>
        <zip>84108</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37678</name>
      <address>
        <city>Bratislava</city>
        <zip>84231</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37836</name>
      <address>
        <city>Bratislava</city>
        <zip>85101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37837</name>
      <address>
        <city>Bratislava</city>
        <zip>85101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37838</name>
      <address>
        <city>Bratislava</city>
        <zip>85101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37861</name>
      <address>
        <city>Bratislava</city>
        <zip>85101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37864</name>
      <address>
        <city>Bratislava</city>
        <zip>85101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37866</name>
      <address>
        <city>Bratislava</city>
        <zip>85101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 25682</name>
      <address>
        <city>Bratislava</city>
        <zip>85104</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37677</name>
      <address>
        <city>Bratislava</city>
        <zip>85105</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37754</name>
      <address>
        <city>Brezno</city>
        <zip>97701</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37755</name>
      <address>
        <city>Brezno</city>
        <zip>97701</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37756</name>
      <address>
        <city>Brezno</city>
        <zip>97701</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37863</name>
      <address>
        <city>Dojc</city>
        <zip>90602</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38048</name>
      <address>
        <city>Dolne Vestenice</city>
        <zip>97223</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37694</name>
      <address>
        <city>Dolny Kubin</city>
        <zip>2601</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38029</name>
      <address>
        <city>Drienov</city>
        <zip>08024</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38056</name>
      <address>
        <city>Dudince</city>
        <zip>962 71</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37688</name>
      <address>
        <city>Galanta</city>
        <zip>92401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37703</name>
      <address>
        <city>Galanta</city>
        <zip>92401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37808</name>
      <address>
        <city>Giraltovce</city>
        <zip>08701</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37708</name>
      <address>
        <city>Horka nad Vahom</city>
        <zip>91632</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38054</name>
      <address>
        <city>Hronske Klacany</city>
        <zip>95329</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37745</name>
      <address>
        <city>Humenne</city>
        <zip>06601</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37752</name>
      <address>
        <city>Humenne</city>
        <zip>06601</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37814</name>
      <address>
        <city>Humenne</city>
        <zip>06601</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37815</name>
      <address>
        <city>Humenne</city>
        <zip>06601</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37687</name>
      <address>
        <city>Jelka</city>
        <zip>92523</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37737</name>
      <address>
        <city>Kosice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37740</name>
      <address>
        <city>Kosice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37741</name>
      <address>
        <city>Kosice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37744</name>
      <address>
        <city>Kosice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37767</name>
      <address>
        <city>Kosice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37788</name>
      <address>
        <city>Kosice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38030</name>
      <address>
        <city>Kosice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38035</name>
      <address>
        <city>Kosice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38040</name>
      <address>
        <city>Kosice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38043</name>
      <address>
        <city>Kosice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37742</name>
      <address>
        <city>Kosice</city>
        <zip>4001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37810</name>
      <address>
        <city>Levoca</city>
        <zip>05401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37811</name>
      <address>
        <city>Levoca</city>
        <zip>05401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37686</name>
      <address>
        <city>Likavka</city>
        <zip>83495</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37690</name>
      <address>
        <city>Lubochna</city>
        <zip>3491</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37790</name>
      <address>
        <city>Lucenec</city>
        <zip>984 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37791</name>
      <address>
        <city>Lucenec</city>
        <zip>98401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37792</name>
      <address>
        <city>Lucenec</city>
        <zip>98401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37793</name>
      <address>
        <city>Lucenec</city>
        <zip>98401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37795</name>
      <address>
        <city>Lucenec</city>
        <zip>98401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37797</name>
      <address>
        <city>Lucenec</city>
        <zip>98401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37798</name>
      <address>
        <city>Lucenec</city>
        <zip>98401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37859</name>
      <address>
        <city>Malacky</city>
        <zip>90101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37865</name>
      <address>
        <city>Malacky</city>
        <zip>90101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37696</name>
      <address>
        <city>Martin</city>
        <zip>3601</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37702</name>
      <address>
        <city>Martin</city>
        <zip>3601</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37706</name>
      <address>
        <city>Martin</city>
        <zip>3601</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37743</name>
      <address>
        <city>Michalovce</city>
        <zip>07101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37766</name>
      <address>
        <city>Michalovce</city>
        <zip>07101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38028</name>
      <address>
        <city>Michalovce</city>
        <zip>07101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37862</name>
      <address>
        <city>Modra</city>
        <zip>90001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38042</name>
      <address>
        <city>Moldava nad Bodvou</city>
        <zip>04501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37697</name>
      <address>
        <city>Namestovo</city>
        <zip>2901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38041</name>
      <address>
        <city>Nitra</city>
        <zip>94901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38050</name>
      <address>
        <city>Nitra</city>
        <zip>94901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38053</name>
      <address>
        <city>Nitra</city>
        <zip>94911</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38036</name>
      <address>
        <city>Nitra</city>
        <zip>94988</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38038</name>
      <address>
        <city>Nitra</city>
        <zip>94988</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38039</name>
      <address>
        <city>Nitra</city>
        <zip>94988</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37692</name>
      <address>
        <city>Nitrianske Pravno</city>
        <zip>3822</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38047</name>
      <address>
        <city>Nitrianske Rudno</city>
        <zip>97226</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38045</name>
      <address>
        <city>Novaky</city>
        <zip>97271</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38049</name>
      <address>
        <city>Oslany</city>
        <zip>97247</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38051</name>
      <address>
        <city>Partizanske</city>
        <zip>95801</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37731</name>
      <address>
        <city>Piestany</city>
        <zip>92101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37858</name>
      <address>
        <city>Piestany</city>
        <zip>92101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37812</name>
      <address>
        <city>Podhradie</city>
        <zip>05304</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37757</name>
      <address>
        <city>Pohorelska Masa</city>
        <zip>97669</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37804</name>
      <address>
        <city>Presov</city>
        <zip>08001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37809</name>
      <address>
        <city>Presov</city>
        <zip>08001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37817</name>
      <address>
        <city>Presov</city>
        <zip>08001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37789</name>
      <address>
        <city>Revuca</city>
        <zip>05001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37799</name>
      <address>
        <city>Revuca</city>
        <zip>05001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37762</name>
      <address>
        <city>Rimavska Sobota</city>
        <zip>97901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37763</name>
      <address>
        <city>Rimavska Sobota</city>
        <zip>97901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37764</name>
      <address>
        <city>Rimavska Sobota</city>
        <zip>97901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37765</name>
      <address>
        <city>Rimavska Sobota</city>
        <zip>97901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37800</name>
      <address>
        <city>Roznava</city>
        <zip>04801</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37801</name>
      <address>
        <city>Roznava</city>
        <zip>04801</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37698</name>
      <address>
        <city>Ruzomberok</city>
        <zip>034 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37693</name>
      <address>
        <city>Ruzomberok</city>
        <zip>3401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37685</name>
      <address>
        <city>Samorin</city>
        <zip>93101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37735</name>
      <address>
        <city>Selice</city>
        <zip>92572</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37733</name>
      <address>
        <city>Senec</city>
        <zip>90301</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37730</name>
      <address>
        <city>Senica</city>
        <zip>90632</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38055</name>
      <address>
        <city>Slatina nad Bebravou</city>
        <zip>95653</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37805</name>
      <address>
        <city>Slovinky</city>
        <zip>05340</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38033</name>
      <address>
        <city>Snina</city>
        <zip>06901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38034</name>
      <address>
        <city>Snina</city>
        <zip>06901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38037</name>
      <address>
        <city>Snina</city>
        <zip>06901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37746</name>
      <address>
        <city>Spisska Nova Ves</city>
        <zip>05201</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37747</name>
      <address>
        <city>Spisska Nova Ves</city>
        <zip>05201</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37748</name>
      <address>
        <city>Spisska Nova Ves</city>
        <zip>05201</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37750</name>
      <address>
        <city>Spisska Nova Ves</city>
        <zip>05201</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37751</name>
      <address>
        <city>Spisska Nova Ves</city>
        <zip>05201</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37813</name>
      <address>
        <city>Spisska Nova Ves</city>
        <zip>05201</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37736</name>
      <address>
        <city>Streda nad Bodrogom</city>
        <zip>07631</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38031</name>
      <address>
        <city>Streda nad Bodrogom</city>
        <zip>07631</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37860</name>
      <address>
        <city>Stupava</city>
        <zip>90101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37816</name>
      <address>
        <city>Svidnik</city>
        <zip>08901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38046</name>
      <address>
        <city>Topolcany</city>
        <zip>95501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37734</name>
      <address>
        <city>Trencin</city>
        <zip>91101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37699</name>
      <address>
        <city>Trencin</city>
        <zip>91105</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37682</name>
      <address>
        <city>Trhova Hradska</city>
        <zip>93013</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37683</name>
      <address>
        <city>Trhova Hradska</city>
        <zip>93013</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37691</name>
      <address>
        <city>Trnava</city>
        <zip>3901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37705</name>
      <address>
        <city>Trnava</city>
        <zip>91701</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37870</name>
      <address>
        <city>Trnava</city>
        <zip>91701</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37701</name>
      <address>
        <city>Trnovec nad Vahom</city>
        <zip>92571</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37695</name>
      <address>
        <city>Turany</city>
        <zip>3853</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38032</name>
      <address>
        <city>Velke Kapusany</city>
        <zip>07901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37868</name>
      <address>
        <city>Velke Kostolany</city>
        <zip>92207</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37760</name>
      <address>
        <city>Velky Krtis</city>
        <zip>99001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37761</name>
      <address>
        <city>Velky Krtis</city>
        <zip>99001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37807</name>
      <address>
        <city>Vranov nad Topľou</city>
        <zip>09301</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37867</name>
      <address>
        <city>Vrbove</city>
        <zip>92203</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37684</name>
      <address>
        <city>Vrutky</city>
        <zip>3861</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38044</name>
      <address>
        <city>Zabokreky nad Nitrou</city>
        <zip>95852</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37689</name>
      <address>
        <city>Zilina</city>
        <zip>1001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37700</name>
      <address>
        <city>Zilina</city>
        <zip>1001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37704</name>
      <address>
        <city>Zilina</city>
        <zip>1001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37707</name>
      <address>
        <city>Zilina</city>
        <zip>1001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37869</name>
      <address>
        <city>Zohor</city>
        <zip>90051</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37794</name>
      <address>
        <city>Zvolen</city>
        <zip>96001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37796</name>
      <address>
        <city>Zvolen</city>
        <zip>96001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37802</name>
      <address>
        <city>Zvolen</city>
        <zip>96001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37803</name>
      <address>
        <city>Zvolen</city>
        <zip>96001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2010</study_first_submitted>
  <study_first_submitted_qc>April 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2010</study_first_posted>
  <results_first_submitted>July 26, 2011</results_first_submitted>
  <results_first_submitted_qc>July 26, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 25, 2011</results_first_posted>
  <last_update_submitted>September 9, 2011</last_update_submitted>
  <last_update_submitted_qc>September 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment with Klacid®SR</keyword>
  <keyword>tracheitis</keyword>
  <keyword>tracheobronchitis</keyword>
  <keyword>bronchitis</keyword>
  <keyword>chronic bronchitis</keyword>
  <keyword>community-acquired pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
    <mesh_term>Tracheitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acute Respiratory Infections</title>
          <description>Slovak participants with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) prescribed Klacid SR 1000 mg once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Population</title>
              <participants_list>
                <participants group_id="P1" count="3181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acute Respiratory Infections</title>
          <description>Slovak participants with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) prescribed Klacid SR 1000 mg once daily.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3181"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than 20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 to 29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 to 39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 to 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 to 59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 to 69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70 to 79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80 years or older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Gender not collected in this study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Gender not collected in this study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <description>The diagnosis of each participant at Baseline.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Acute tracheobronchitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute bronchitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute tracheitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute exacerbation of chronic bronchitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild community-acquired bronchopneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Compliance (Was the Dosage Followed - Yes, no)</title>
        <description>Compliance was assessed by asking physicians if participants took their medication as directed and if not, the reason for noncompliance. The number of participants that completed their course of therapy or did not complete due to noncompliance is reported.</description>
        <time_frame>Day 10 - 16</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Respiratory Infections</title>
            <description>Slovak participants with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) prescribed Klacid SR 1000 mg once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance (Was the Dosage Followed - Yes, no)</title>
          <description>Compliance was assessed by asking physicians if participants took their medication as directed and if not, the reason for noncompliance. The number of participants that completed their course of therapy or did not complete due to noncompliance is reported.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Completed course of therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not complete (lost to follow-up)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not complete (noncompliance)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;Participant felt better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;Reason not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Tolerability of Klacid SR Will be Assessed by Evaluation of Adverse Events</title>
        <description>The number of participants experiencing adverse events, serious adverse events, or adverse events leading to study discontinuation are summarized. See Reported Adverse Events for additional details.</description>
        <time_frame>Day 0 through Days 10 - 16</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Respiratory Infections</title>
            <description>Slovak participants with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) prescribed Klacid SR 1000 mg once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>The Tolerability of Klacid SR Will be Assessed by Evaluation of Adverse Events</title>
          <description>The number of participants experiencing adverse events, serious adverse events, or adverse events leading to study discontinuation are summarized. See Reported Adverse Events for additional details.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-serious adverse events (AEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Temperature</title>
        <description>Body temperature was measured at Day 0 (Baseline) and 10 to 16 days later (Visit 2). Increased body temperature was defined as body temperature greater than or equal to 37 degrees Celsius/98.6 Fahrenheit. The percentage of participants with increased or normal body temperature at Day 0 (Baseline) is summarized.</description>
        <time_frame>Day 0</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Respiratory Infections</title>
            <description>Slovak participants with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) prescribed Klacid SR 1000 mg once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Temperature</title>
          <description>Body temperature was measured at Day 0 (Baseline) and 10 to 16 days later (Visit 2). Increased body temperature was defined as body temperature greater than or equal to 37 degrees Celsius/98.6 Fahrenheit. The percentage of participants with increased or normal body temperature at Day 0 (Baseline) is summarized.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Body temperature greater than 37 ºC at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body temperature less than 37 ºC at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body temperature not reported at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Temperature</title>
        <description>Body temperature was measured at Day 0 (Baseline) and 10 to 16 days later (Visit 2). Increased body temperature was defined as body temperature greater than or equal to 37 degrees Celsius/98.6 Fahrenheit. The percentage of participants with increased or normal body temperature at Visit 2 is summarized.</description>
        <time_frame>Day 10 - 16</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Respiratory Infections</title>
            <description>Slovak participants with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) prescribed Klacid SR 1000 mg once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Temperature</title>
          <description>Body temperature was measured at Day 0 (Baseline) and 10 to 16 days later (Visit 2). Increased body temperature was defined as body temperature greater than or equal to 37 degrees Celsius/98.6 Fahrenheit. The percentage of participants with increased or normal body temperature at Visit 2 is summarized.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Body temperature greater than 37 ºC at Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body temperature less than 37 ºC at Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body temperature not reported at Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cough and Its Character</title>
        <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The presence of cough and the type of cough (productive or irritating) was determined by the treating physician based on clinical judgment. The number of participants with each type of cough or no cough at Baseline is presented.</description>
        <time_frame>Day 0</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Respiratory Infections</title>
            <description>Slovak participants with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) prescribed Klacid SR 1000 mg once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Cough and Its Character</title>
          <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The presence of cough and the type of cough (productive or irritating) was determined by the treating physician based on clinical judgment. The number of participants with each type of cough or no cough at Baseline is presented.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Had irritating cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Had productive cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not have cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presence or absence of cough not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cough and Its Character</title>
        <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The presence of cough and the type of cough (productive or irritating) was determined by the treating physician based on clinical judgment. The number of participants with each type of cough or no cough at Visit 2 is presented.</description>
        <time_frame>Day 10 - 16</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Respiratory Infections</title>
            <description>Slovak participants with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) prescribed Klacid SR 1000 mg once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Cough and Its Character</title>
          <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The presence of cough and the type of cough (productive or irritating) was determined by the treating physician based on clinical judgment. The number of participants with each type of cough or no cough at Visit 2 is presented.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Had irritating cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Had productive cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not have cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presence or absence of cough not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dyspnoea</title>
        <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The treating physicians used their clinical judgment to determine the presence of dyspnoea (difficulty breathing) and whether it occurred while resting or after exertion. The number of participants with each type of dyspnoea or with no dyspnoea at Baseline is presented.</description>
        <time_frame>Day 0</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Respiratory Infections</title>
            <description>Slovak participants with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) prescribed Klacid SR 1000 mg once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Dyspnoea</title>
          <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The treating physicians used their clinical judgment to determine the presence of dyspnoea (difficulty breathing) and whether it occurred while resting or after exertion. The number of participants with each type of dyspnoea or with no dyspnoea at Baseline is presented.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Had resting dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Had exertional dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not have dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presence or absence of dyspnoea not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dyspnoea</title>
        <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The treating physicians used their clinical judgment to determine the presence of dyspnoea (difficulty breathing) and whether it occurred while resting or after exertion. The number of participants with each type of dyspnoea or with no dyspnoea at Visit 2 is presented.</description>
        <time_frame>Day 10 - 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute Respiratory Infections</title>
            <description>Slovak participants with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) prescribed Klacid SR 1000 mg once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Dyspnoea</title>
          <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The treating physicians used their clinical judgment to determine the presence of dyspnoea (difficulty breathing) and whether it occurred while resting or after exertion. The number of participants with each type of dyspnoea or with no dyspnoea at Visit 2 is presented.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Had resting dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Had exertional dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not have dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presence or absence of dyspnoea not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Auscultation</title>
        <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The treating physician used their clinical judgment to determine the presence of abnormal breathing sounds such as wheezing or crackles using auscultation (listening for sounds within the body, usually with a stethoscope in the chest, neck or abdomen). The number of participants with each type of breath sound at Baseline is summarized.</description>
        <time_frame>Day 0</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Respiratory Infections</title>
            <description>Slovak participants with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) prescribed Klacid SR 1000 mg once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Auscultation</title>
          <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The treating physician used their clinical judgment to determine the presence of abnormal breathing sounds such as wheezing or crackles using auscultation (listening for sounds within the body, usually with a stethoscope in the chest, neck or abdomen). The number of participants with each type of breath sound at Baseline is summarized.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal breath sounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crackles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breath sounds not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Auscultation</title>
        <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The treating physician used their clinical judgment to determine the presence of abnormal breathing sounds such as wheezing or crackles using auscultation (listening for sounds within the body, usually with a stethoscope in the chest, neck or abdomen). The number of participants with each type of breath sound at Visit 2 is summarized.</description>
        <time_frame>Day 10 - 16</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Respiratory Infections</title>
            <description>Slovak participants with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) prescribed Klacid SR 1000 mg once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Auscultation</title>
          <description>Participants were evaluated at Day 0 (Baseline) and 10 to 16 days later (Visit 2). The treating physician used their clinical judgment to determine the presence of abnormal breathing sounds such as wheezing or crackles using auscultation (listening for sounds within the body, usually with a stethoscope in the chest, neck or abdomen). The number of participants with each type of breath sound at Visit 2 is summarized.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal breath sounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crackles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breath sounds not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected through Visit 2 (10 to 16 days).</time_frame>
      <desc>Adverse events are based on the per-protocol population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Acute Respiratory Infections</title>
          <description>Slovak participants with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) prescribed Klacid SR 1000 mg once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea, abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3181"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3181"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3181"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3181"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3181"/>
              </event>
              <event>
                <sub_title>Vomiting, transient exanthema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache, nausea, bad taste in mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>Abbott</organization>
      <phone>1-800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

